Mirum says brelovitug hits primary endpoint in Phase 3 AZURE-4 trial for hepatitis deltaNov 10Clinical readoutbulevirtideMirum Pharmaceuticals, Inc.
Mirum reports four positive readouts, raises 2026 sales guidance to $715M-$720MNov 3Quarterly updatebulevirtidemaralixibat
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
FDA approves Mirum and Incyte's Atebrioz for FOP; brelovitug hits Phase 3 HDV endpointSep 28Regulatory decisionbulevirtideMirum Pharmaceuticals, Inc.
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underwayAug 5Quarterly updateVir Biotechnology, Inc.VIR-5500
Mirum raises 2026 sales guidance, volixibat gets FDA breakthrough status for PSCAug 5Quarterly updateMirum Pharmaceuticals, Inc.volixibat
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readoutsAug 4Quarterly updateGilead Sciences